ERBB2 and breast cancer: The identification of lactate quantification as a novel, noninvasive, and reliable metabolic biomarker of addiction to HER2 signaling may improve the selection of HER2‐positive BC patients who are more likely to benefit from standard anti‐HER2 treatments, while unselected patients are steered towards enrollment in clinical trials.